Skip to main content

Table 1 Patients’ characteristics at baseline, by HBeAg status

From: Serum O-glycosylated hepatitis B surface antigen levels in patients with chronic hepatitis B during nucleos(t)ide analog therapy

Characteristics

All patients (n = 47)

HBeAg positive (n = 25)

HBeAg negative (n = 22)

Age (years)

55 (27–80)

55 (27–80)

57 (35–80)

Males

31 (70.0)

15 (60.0)

16 (72.7)

Albumin (g/dL)

4.1 (2.4–4.6)

4.0 (2.4–4.6)

4.1 (3.5–4.6)

ALT (IU/L)

58 (14–538)

72 (29–522)

45 (14–538)

Total bilirubin (mg/dL)

0.8 (0.3–3.7)

0.8 (0.4–2.4)

0.9 (0.3–3.7)

Cirrhosis

14 (29.8)

6 (24.0)

8 (36.4)

HBV-DNA (log IU/mL)

5.7 (1.3–8.2)

6.8 (1.7–8.2)

4.4 (1.3–7.7)

HBsAg (log IU/mL)

3.3 (− 0.1 to 4.8)

3.5 (2.7–4.8)

3.3 (− 0.1 to 4.0)

HBcrAg (log U/mL)

5.7 (2.9–7.0)

7.0 (5.4–7.0)

4.1 (2.9–6.4)

  1. Data are expressed as median (range) or number (%)
  2. ALT alanine aminotransferase, HBcrAg hepatitis B core-related antigen, HBeAg hepatitis B e antigen, HBsAg hepatitis B surface antigen, HBV hepatitis B virus